Objective: We evaluated in our study the effects of Growth Hormon Release (GHR) which is claimed as a natural modulator of Growth Hormone (GH) secretion at pituitary level, on coronary artery disease patients who don't have the possibility of mechanical revascularization.

Materials and Methods: 67 patients who don't have the chance of mechanical revascularization due to the results of angiographic analysis were included in the study. After the standardization of anti-ischemia treatment, patients were evaluated clinically for basal homodynamic data, life quality criteria, limits of exertional capacity, and Duke treadmill scores (DTS) and then for 12 weeks GHR was given to the first group (n:38) and placebo was given to the other group(n:36). At the end of 12 weeks besides all the hemodynamic parameters; evaluation of all the patients was repeated for life quality criteria, limits of exertional capacity and DTS.

Results: Basal clinical demographic characteristics of two groups were similar (p>0.05). Although 41 % decrease in weekly nitrate consumption (p:0.01), 39% decrease in weekly angina pectoris attacks (p:0.01), an increase of 98 seconds (p:0.01) in the mean period to 1 mm ST depression in treadmill and 40 % improvement in DTS (p:0.02) were seen in GHR group, there was no statistically significant change in placebo group (p>0.05).

Conclusion: We believe that added-on GHR therapy on standard anti-ischemia treatment protocol in patients who don't have the chance of mechanical revascularization may improve the quality of life.